Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPFGet Rating) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 46,100 shares, a growth of 45.9% from the March 31st total of 31,600 shares. Based on an average daily trading volume, of 12,500 shares, the short-interest ratio is presently 3.7 days.

ATBPF opened at $0.56 on Friday. Antibe Therapeutics has a one year low of $0.44 and a one year high of $3.70. The stock’s fifty day moving average is $0.59 and its 200-day moving average is $0.60. The company has a market capitalization of $29.07 million, a PE ratio of -1.33 and a beta of 0.22.

Antibe Therapeutics (OTCMKTS:ATBPFGet Rating) last posted its quarterly earnings data on Monday, February 14th. The company reported ($0.08) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.05. Antibe Therapeutics had a negative return on equity of 42.02% and a negative net margin of 244.59%. Research analysts expect that Antibe Therapeutics will post -0.33 earnings per share for the current fiscal year.

Antibe Therapeutics Company Profile (Get Rating)

Antibe Therapeutics Inc, a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.

See Also

Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with's FREE daily email newsletter.